Masimo (NASDAQ:MASI – Get Free Report) is projected to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $1.41 per share and revenue of $407.9730 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.
Masimo Stock Performance
Shares of Masimo stock opened at $175.25 on Tuesday. The company has a market capitalization of $9.41 billion, a PE ratio of -16.63, a P/E/G ratio of 1.77 and a beta of 1.26. The company has a 50-day simple moving average of $139.89 and a two-hundred day simple moving average of $143.22. Masimo has a one year low of $125.94 and a one year high of $194.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84.
Hedge Funds Weigh In On Masimo
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC purchased a new stake in Masimo during the 4th quarter valued at about $27,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Masimo during the fourth quarter worth about $28,000. Los Angeles Capital Management LLC acquired a new stake in shares of Masimo during the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in Masimo in the fourth quarter valued at approximately $38,000. Finally, Advisory Services Network LLC acquired a new position in Masimo in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Report on MASI
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.
In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.
Featured Stories
- Five stocks we like better than Masimo
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Elon Musk: This Could Turn $100 into $100,000
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.
